Professional Documents
Culture Documents
OMM PP A
ANN YY RR EE PP O
O RR TT
KLBF
KALBE FARMA TBK.
Company Profile
PTKalbeFarmaTbk.wasestablisheddatedSeptember10th,1966,withintheframeworkof
theDomesticCapitalInvestmentLaw.
ThescopeofactivitiesoftheCompanycomprises,amongothers,pharmaceuticals,trading
and representative. Currently, the Company is primarily engaged in the development,
manufacturing, and trading of pharmaceuticals preparation including medicines and
consumerhealthproducts.TheCompanystarteditscommercialoperationsin1966.
TheSubsidiariesareengagedin:
the Pharmaceutical: PT Bintang Toedjoe,PT Hexpharm Jaya Laboratories, PT Saka Farma
Laboratories, PT Finusolprima Farma Internasional, PT Bifarma Adiluhung, Innogene
KalbiotechPte.Ltd.,PTDankosFarma,PTPharmaMetricLabs.,PTKalGenDNA,PTKalbio
GlobalMedika.
Health Foods and Drinks: PT Sanghiang Perkasa, PT Kalbe Morinaga Indonesia, PT Hale
International,PTKalbeMilkoIndonesia.
SaleandDistribution:PTEnsevalPuteraMegatradingTbk.,PTTriSaptaJaya,PTMillenia
DharmaInsani,PTEnsevalMedikaPrima,PTGlobalChemindoMegatrading,PTRenalmed
Tiara Utama, PT Medika Renal Citraprima, Kalbe Vision Pte. Ltd., Kalbe International Pte.
Ltd.,AsiawideKalbePhilippinesInc.,PTKarsaLintasBuwana,KalbeMayiaSdn.Bhd.
The Companys production plants is located at Kawasan Industri Delta Silicon, Jln. M.H.
Thamrin,BlockA31,LippoCikarang,Bekasi.
AsofJune30th,2016,theGrouphadacombinedtotalof13,405permanentemployees.
August 2016
Disclaimer:
The facts and opinions stated or expressed in this publication are for information purposes only and are not necessarily and must not be relied upon as being those of the publisher or
of the institutions for which the contributing authors work. Although every care has been taken to ensure the accuracy of the information contained within the publication it should not be
by any person relied upon as the basis for taking any action or making any decision. The Indonesia Stock Exchange cannot be held liable or otherwise responsible in anyway for any
advice action taken or decision made on the basis of the facts and opinions stated or expressed or stated within this publication.
KLBF Kalbe Farma Tbk. [S]
COMPANY REPORT : JULY 2016 As of 29 July 2016
Main Board Individual Index : 16,336.682
Industry Sector : Consumer Goods Industry (5) Listed Shares : 46,875,122,110
Industry Sub Sector : Pharmaceuticals (53) Market Capitalization : 78,515,829,534,250
12 | 78.5T | 1.40% | 50.94%
Day
Closing Volume
Price* January 2012 - July 2016 (Mill. Sh) Month High Low Close (X) (Thou. Sh.) (Million Rp)
2,000 400 Jan-12 3,650 3,375 3,525 15,399 122,271 428,028 21
Feb-12 3,600 3,400 3,500 18,914 172,533 602,764 21
1,750 350 Mar-12 3,550 3,375 3,550 18,538 283,565 982,054 21
Apr-12 4,050 3,400 4,025 31,628 485,446 1,795,766 20
May-12 4,025 3,750 3,875 39,920 454,029 1,783,899 21
1,500 300
Jun-12 4,000 3,700 3,775 30,929 384,956 1,485,524 21
Jul-12 3,900 3,675 3,825 32,278 394,523 1,497,405 22
1,250 250
Aug-12 4,000 3,750 3,875 33,041 255,670 999,731 19
Sep-12 4,700 3,900 4,700 33,617 272,454 1,158,254 20
1,000 200
Oct-12 4,975 910 970 54,533 779,898 998,575 22
Nov-12 1,040 960 1,030 68,691 1,528,172 1,514,316 20
750 150 Dec-12 1,150 980 1,060 53,129 1,506,913 1,585,510 18
BALANCE SHEET Dec-12 Dec-13 Dec-14 Dec-15 Jun-16 TOTAL ASSETS AND LIABILITIES (Bill. Rp)
(Million Rp except Par Value) Assets Liabilities
Cash & Cash Equivalents 1,859,663 1,426,461 1,894,610 2,718,619 2,175,668 15,000
7,372
Retained Earnings 7,250,739 7,633,188 8,900,998 10,006,398 10,261,984
6,651
13,636
14,238
Comprehensive Income 1,772,035 2,004,244 2,129,215 2,083,403 1,188,945 2012 2013 2014 2015 Jun-16
Comprehensive Attributable 1,730,864 1,952,589 2,072,781 2,029,813 1,161,641
RATIOS Dec-12 Dec-13 Dec-14 Dec-15 Jun-16 PROFIT FOR THE PERIOD (Bill. Rp)
Current Ratio (%) 340.54 283.93 340.36 369.78 343.50
2,121 2,058
Dividend (Rp) 19.00 17.00 19.00 19.00 - 2,121 1,970
28.45 37.80 44.05 42.76 24.45 1,775
EPS (Rp)
BV (Rp) 120.97 167.39 209.44 233.35 239.66 1,688
DER(X)
ROA (%) 18.85 17.41 17.07 15.02 8.24 823
OPM (%) - - - - -
NPM (%) 13.02 12.31 12.21 11.50 12.27
-42